Oppenheimer analyst Leland Gershell initiated coverage of Catalyst Pharmaceuticals with an Outperform rating and $30 price target. The firm’s physician survey indicates that the market is underestimating Agamree’s launch for Duchenne muscular dystrophy, or DMD, and the firm expects the treatment to “quickly ramp” toward its roughly $300M peak sales projection.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CPRX:
- Catalyst Pharmaceuticals announces submission of FIRDAPSE NDA in Japan
- Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma
- Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America’s Most Successful Small-Cap Companies
- Catalyst Pharmaceuticals appoints Kalb as CFO, announces other promotions
- Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions
